NICE recommends epcoritamab for relapsed follicular lymphoma, offering a new option after multiple lines of therapy.
A replay of the corporate presentation will be available on the Events section of the Company’s Investor Relations website.
India’s EV boom is creating a ₹16 bn battery opportunity. Three chemical players are betting big on next-gen materials.
Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for cancer, today announced that the U.S. Food and Drug ...
In early January, the U.S. Department of Health and Human Services removed the recommendation for universal vaccination ...
Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events Company expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial in ...
Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO; results surpass current standards of care RARITAN, N.J., Feb. 19 ...
The interim analysis of the BCG-Unresponsive cohort includes 35 evaluable participants, of whom, 22 were evaluable at six months and 15 were evaluable at 12 months as of a January 28, 2026 data cutoff ...
In a new study, researchers found microplastics deep inside prostate cancer tumors, raising more questions about the role the ...
Phase 3 trial results show BIC/LEN is noninferior to BIC/FTC/TAF for maintaining virologic suppression in adults with HIV.
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Biotechnology industry for Wednesday, February 25, 2026. Let’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results